Compare TBBK & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | IDYA |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | 733 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.9B |
| IPO Year | 2005 | 2019 |
| Metric | TBBK | IDYA |
|---|---|---|
| Price | $53.55 | $33.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $69.00 | $51.21 |
| AVG Volume (30 Days) | 477.7K | ★ 749.4K |
| Earning Date | 04-30-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.69 | ★ 61.90 |
| EPS | ★ 4.92 | N/A |
| Revenue | $141,147,000.00 | ★ $218,710,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.90 | $213.03 |
| P/E Ratio | $10.82 | ★ N/A |
| Revenue Growth | 20.85 | ★ 3024.43 |
| 52 Week Low | $40.51 | $13.45 |
| 52 Week High | $81.65 | $39.28 |
| Indicator | TBBK | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 47.55 |
| Support Level | $49.11 | $29.15 |
| Resistance Level | $53.83 | $33.64 |
| Average True Range (ATR) | 2.28 | 1.32 |
| MACD | 0.18 | 0.11 |
| Stochastic Oscillator | 38.54 | 37.61 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.